CN114349852A - 抗h3n2流感病毒血凝素蛋白单克隆抗体zju32-01及其在检测中的应用 - Google Patents
抗h3n2流感病毒血凝素蛋白单克隆抗体zju32-01及其在检测中的应用 Download PDFInfo
- Publication number
- CN114349852A CN114349852A CN202210039523.1A CN202210039523A CN114349852A CN 114349852 A CN114349852 A CN 114349852A CN 202210039523 A CN202210039523 A CN 202210039523A CN 114349852 A CN114349852 A CN 114349852A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- influenza virus
- zju32
- hemagglutinin protein
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 41
- 101710154606 Hemagglutinin Proteins 0.000 title claims abstract description 28
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title claims abstract description 28
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title claims abstract description 28
- 101710176177 Protein A56 Proteins 0.000 title claims abstract description 28
- 238000001514 detection method Methods 0.000 title claims abstract description 14
- 241000252870 H3N2 subtype Species 0.000 claims abstract description 41
- 230000001932 seasonal effect Effects 0.000 claims abstract description 8
- 238000010166 immunofluorescence Methods 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims description 45
- 210000004408 hybridoma Anatomy 0.000 claims description 30
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 9
- 238000010367 cloning Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 17
- 238000005516 engineering process Methods 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000005406 washing Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 206010003445 Ascites Diseases 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- 241000271566 Aves Species 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 6
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000001261 affinity purification Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108050007411 Immunoglobulin subtype Proteins 0.000 description 2
- 102000018297 Immunoglobulin subtype Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- ZPWMEWYQBWSGAO-ZJDVBMNYSA-N Arg-Thr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZPWMEWYQBWSGAO-ZJDVBMNYSA-N 0.000 description 1
- HUZGPXBILPMCHM-IHRRRGAJSA-N Asn-Arg-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HUZGPXBILPMCHM-IHRRRGAJSA-N 0.000 description 1
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- LTARLVHGOGBRHN-AAEUAGOBSA-N Asp-Trp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(O)=O LTARLVHGOGBRHN-AAEUAGOBSA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 1
- BBQIWFFTTQTNOC-AVGNSLFASA-N Cys-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N BBQIWFFTTQTNOC-AVGNSLFASA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
- DWBBKNPKDHXIAC-SRVKXCTJSA-N Glu-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O DWBBKNPKDHXIAC-SRVKXCTJSA-N 0.000 description 1
- CGWHAXBNGYQBBK-JBACZVJFSA-N Glu-Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)N)C(O)=O)C1=CC=C(O)C=C1 CGWHAXBNGYQBBK-JBACZVJFSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- HNFUGJUZJRYUHN-JSGCOSHPSA-N Phe-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HNFUGJUZJRYUHN-JSGCOSHPSA-N 0.000 description 1
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 1
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- ZUDXUJSYCCNZQJ-DCAQKATOSA-N Ser-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)N ZUDXUJSYCCNZQJ-DCAQKATOSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 1
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 1
- CURFABYITJVKEW-QTKMDUPCSA-N Thr-Val-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O CURFABYITJVKEW-QTKMDUPCSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- YTCNLMSUXPCFBW-SXNHZJKMSA-N Trp-Ile-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O YTCNLMSUXPCFBW-SXNHZJKMSA-N 0.000 description 1
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 1
- 108010064997 VPY tripeptide Proteins 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 108010022588 methionyl-lysyl-proline Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供抗H3N2流感病毒血凝素蛋白的单克隆抗体ZJU32‑01及其在检测中的应用。一种抗H3N2流感病毒血凝素蛋白单克隆抗体ZJU32‑01,该单克隆抗体亚型为IgG1、κ型,能与H3N2流感病毒血凝素蛋白抗原特异结合。抗体的重链氨基酸序列如SEQ ID No.2,轻链氨基酸序列如SEQ ID No.4所示。对该单克隆抗体进行进一步的理化性状分析和鉴定,并建立了以该单克隆抗体为探针通过免疫荧光技术检测H3N2流感病毒的方法。本发明为临床样本中H3N2季节性流感病毒感染的辅助诊断提供了有效的工具,并可推广应用于多种检测技术以及临床和实验研究。
Description
技术领域
本发明属于生物技术领域,涉及抗H3N2流感病毒血凝素蛋白单克隆抗体的制备及应用,是利用细胞工程、抗体工程技术,获得分泌抗血凝素蛋白的单克隆抗体的杂交瘤细胞系,通过同品系的小鼠诱导腹水,制备抗血凝素蛋白的单克隆抗体ZJU32-01,鉴定为IgG1、κ型,再通过亲和纯化、电泳、免疫等技术实现对该抗体的应用。
背景技术
目前,与人类季节性流感感染密切相关的流感病毒主要包括两种甲型流感病毒(H1N1和H3N2)和两种谱系(Victoria系和Yamagata系)的乙型流感病毒。据统计,季节性流感每年可导致全球65万人死亡,对公众健康和社会经济带来严重的影响。当前流感疫苗接种仍然是预防流感病毒感染的最佳方法。但是由于流感疫苗与流行病毒株的不匹配等原因,2004年至2015年期间流感疫苗针对H3N2流感病毒感染的有效性仅为33%。因此快速明确实验室诊断、对流感病毒准确分型,可以加深临床对流感流行和致病力的认识,提高流感病例的诊疗效果。
当前最常用的甲型流感病毒检测方法是基于核酸序列的特异性检测方法,例如逆转录PCR。然而,许多实验室可能不具备进行分子检测的能力,更愿意采用技术要求较低的检测方法来识别甲型流感病毒亚型。用于亚型分型的传统血凝抑制试验是一种耗时且繁琐的方法。
当前甲型流感病毒感染的诊断方法主要包括病毒分离鉴定、血清学方法和分子生物学方法,如逆转录酶聚合酶链反应和实时定量聚合酶链反应。但是上述方法都需要特殊设备和条件,对于某些条件落后的地区并不适合。已有许多研究开发了针对不同亚型的特异性单克隆抗体,并试图将其用于临床检测。因此,本发明旨在说明一株针对H3N2甲型流感病毒的特异性单克隆抗体,并将其与免疫荧光技术结合,可以对样本中H3N2季节性流感病毒株进行检测。
综上所述,开发H3N2流感病毒单克隆抗体,用于快速灵敏检测方法的建立迫在眉睫。基于以上背景,本项目选定血凝素蛋白为靶抗原,采用融合杂交瘤技术建立稳定分泌抗血凝素蛋白单克隆抗体的杂交瘤细胞系,并大量制备、纯化和鉴定这些单克隆抗体。该单克隆抗体的获得为建立H3N2季节性流感病毒免疫学诊断方法奠定物质基础,同时对疾病发病机理、预后及疗效判定等方面的研究起到重要作用。
本发明用到杂交瘤细胞技术。该技术将免疫小鼠的B淋巴细胞与骨髓瘤细胞融合,以建立分泌均质抗体的杂交瘤细胞系,也称为单克隆抗体技术。该技术涉及到动物免疫、细胞培养、细胞融合、细胞克隆培养和免疫测定等一系列方法。
发明内容
本发明的目的是提供一种抗H3N2流感病毒血凝素蛋白单克隆抗体,能识别H3N2流感病毒。该单克隆抗体亚型为IgG1、κ型,命名为ZJU32-01,能特异性识别流感病毒的血凝素蛋白。
SEQ ID No.1
Heavy chain:DNA sequence(351bp)
Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
CAGGTTCAACTACAGCAGTCTGGAGCTGAGCTGATGAAGCCTGGGGCCTCAGTGAAGA
TATCCTGCAAGGCTACTGGCTACATATTCAGTAGCTACTGGATAGAATGGGTAAAGCAG
AGGCCTGGACATGGCCTTGAGTGGATTGGAGAGATTTTACCTGGAAGTGGTAGGACTA
ACTACAAAGAGATTTTCAAGGGCAAGGCCACATTCACTGCAGATACATCCTCCAACAC
AGCCTACATGCAACTCAGCAGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTGCAA
GAACTCGGACTACCGGTAGTAGCGACTGGGGCCAAGGCACCACTCTCACAGTCTCCTC
A
SEQ ID No.2
Heavy chain:Amino acid sequence(117AA)
Signal peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
QVQLQQSGAELMKPGASVKISCKATGYIFSSYWIEWVKQRPGHGLEWIGEILPGSGRTNY
KEIFKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCARTRTTGSSDWGQGTTLTVSS
SEQ ID No.3
Light chain:DNA sequence(336bp)
Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
GATGTTTTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTC
CATCTCTTGCAGATCTAGTCAGACTACTGTACATAGTAATGGAAACACCTATTTAGAATG
GTACCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGA
TTTTTTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCA
AGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTTCACAT
GTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAASEQ ID No.4
Light chain:Amino acid sequence(112AA)
Signal peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
DVLMTQTPLSLPVSLGDQASISCRSSQTTVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFF
GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK
本发明的第二个目的提供抗H3N2流感病毒血凝素蛋白单克隆抗体的制备方法,通过以下步骤和技术方案实现:
(1)动物的免疫:选择6周龄的BALB/C小鼠,以纯化的H3N2流感病毒血凝素蛋白对小鼠进行免疫。血凝素蛋白由H3N2流感病毒疫苗株(A/Texas/50/2012)接种鸡胚,培养并收获病毒液,经甲醛灭活、纯化、裂解及再纯化等方法,以磷酸缓冲液稀释制备获得。
(2)小鼠骨髓瘤细胞的培养:培养小鼠骨髓瘤细胞SP2/0并使之保持良好的生长状态用于细胞融合。
(3)细胞融合:采用聚乙二醇融合法。以BALB/C小鼠腹腔巨噬细胞作为饲养细胞,在融合前一天,接种BALB/C小鼠腹腔巨噬细胞于96孔培养板,含20%牛血清的次黄嘌呤-鸟嘌呤-磷酸核糖转移酶培养基培养一天。将(1)中备好的小鼠处死,获取脾脏淋巴细胞。收集(2)中的小鼠骨髓瘤细胞。将上述两种细胞混合离心,然后以聚乙二醇介导细胞融合。融合后的细胞适当稀释,接种至饲养细胞培养板,适当条件培养。
(4)杂交瘤细胞的筛选:将上述培养物在次黄嘌呤-磷酸核糖转移酶选择性培养基中培养。在细胞集落长到大小合适时,吸取细胞培养上清液做抗体鉴定,筛选阳性克隆。
(5)杂交瘤细胞的克隆化:以有限稀释法克隆杂交瘤细胞,将稀释到一定密度的细胞接种至96孔板,使每孔只有一个细胞生长。形成细胞集落的孔取培养上清液做酶联免疫吸附实验,鉴定阳性克隆。重复有限稀释克隆若干次,直到杂交瘤细胞的阳性孔率达到100%。将克隆化后的杂交瘤细胞扩大培养做抗体鉴定及理化性状分析。
(6)单克隆抗体腹水的诱导:在接种杂交瘤细胞前一周,给BALB/C小鼠腹腔注射石蜡油每只0.5毫升,然后每只接种5×106个阳性杂交瘤细胞,10天后收集腹水离心,测定抗体效价,并纯化单克隆抗体。
(7)单克隆抗体的纯化:利用Protein G亲和纯化法纯化腹水中的单克隆抗体。
(8)本发明得到一个产生抗H3N2流感病毒血凝素蛋白单克隆抗体杂交瘤系,即ZJU32-01,ZJU32-01杂交瘤细胞系经4次克隆化,持续培养六月余,分泌抗体稳定。该细胞株经液氮冻存,复苏后生长良好,抗体分泌未见衰退。酶联免疫吸附间接法实验测得ZJU32-01培养上清效价为1:64,腹水效价为1:2048。经单克隆抗体免疫球蛋白亚型分析显示该杂交瘤细胞产生的抗体类型为IgG1。
本发明提供产生单克隆抗体的杂交瘤细胞,它是由免疫的BALB/C小鼠脾细胞和小鼠骨髓瘤细胞SP2/0经融合、筛选、克隆、传代和反复冻存、复苏后获得的小鼠杂交瘤细胞系ZJU32-01,能稳定分泌抗H3N2流感病毒血凝素蛋白的单克隆抗体ZJU32-01。
本发明的另一个目的是提供该单克隆抗体ZJU32-01在含有H3N2流感病毒的体液、尿囊液或其他环境样本中的检测中的应用,通过免疫荧光技术实现。
本发明还提供一种H3N2流感病毒检测产品,包含单克隆抗体ZJU32-01。
本发明的优点在于提供了一种抗H3N2流感病毒血凝素蛋白的单克隆抗体。制备方法简单易行,更为重要的是该方法制备的单克隆抗体可以有多种用途,如对临床和实验室的H3N2流感样本进行定性诊断。
说明书附图
图1为单克隆抗体ZJU32-01的免疫球蛋白亚型分析。
图2为免疫荧光技术检测H3N2流感病毒的特异性。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。
实施例1.抗H3N2流感病毒血凝素蛋白的单克隆抗体的制备方法
(1)小鼠的免疫:首次免疫,将H3N2流感病毒血凝素全蛋白与佐剂按等体积混合均匀,总体积600微升。每只BALB/C小鼠0.1毫升(含H3N2流感病毒血凝素全蛋白抗原30微克),大腿内侧肌肉注射。第21天按同样方式加强免疫一针。第35天采微量尾血进行酶联免疫吸附实验测定,抗体滴度达到1:32000,随即尾静脉注射加强免疫一次,于3天后进行细胞融合。
(2)小鼠骨髓瘤细胞SP2/0的培养:把来自BALB/C小鼠的SP2/0骨髓瘤细胞株以含10%牛血清DMEM培养基培养传代,在含5%二氧化碳饱和37℃孵箱中培养。融合前一天传代以保证融合时细胞进入对数生长期。
(3)细胞融合:以BALB/C小鼠腹腔巨噬细胞作为饲养细胞,在融合前一天,接种BALB/c小鼠腹腔巨噬细胞于96孔培养板,含20%牛血清的次黄嘌呤-鸟嘌呤-磷酸核糖转移酶培养基培养一天。次日取(1)中小鼠脾脏,采用压力注水法分离脾细胞,离心洗涤细胞2次后用培养液重悬。收集(2)中SP2/0细胞,离心,洗涤2次后用培养液重悬,作为待融合的SP2/0细胞。以1×108个免疫小鼠脾淋巴细胞与2×107个小鼠骨髓瘤细胞SP2/0混合,在聚乙二醇作用下融合。两种细胞混合后洗涤一次,离心弃上清,轻弹管壁悬开细胞,用37℃预温的聚乙二醇0.9毫升于90秒内逐滴加入细胞沉淀中,其间轻轻振摇离心管,但勿吹打,静置1分钟,然后按先慢后快的原则,于第1分钟内加完1毫升无血清DMEM,于第2分钟内加完2毫升无血清DMEM,于第3分钟内加完7毫升无血清DMEM,以后1分钟内逐渐加入37℃预温的无血清DMEM培养基40毫升。1000转每分钟低速离心10分钟。然后加入培养基,分别接种到加有饲养细胞的96孔培养板,置细胞孵箱中培养。
(4)杂交瘤细胞的筛选:每隔4天换一半培养液(含次黄嘌呤-鸟嘌呤-磷酸核糖转移酶)一次,10天后改用含次黄嘌呤-磷酸核糖转移酶培养液。融合后的杂交瘤细胞在含次黄嘌呤-磷酸核糖转移酶的选择性培养液中大约持续培养两周。吸取培养上清做酶联免疫吸附实验,筛选阳性克隆。采用酶联免疫吸附实验间接法筛选阳性杂交瘤克隆。主要步骤:①0.01摩尔每升pH9.6碳酸盐缓冲液稀释H3N2血凝素蛋白,浓度20纳克/孔,分别于96孔酶标板加入0.1毫升每孔,4℃过夜;②0.01摩尔每升pH7.4磷酸盐缓冲液(含吐温20)洗板三次;③用5%牛血清白蛋白0.01摩尔每升pH 7.4的磷酸盐缓冲液封闭2小时;④同上洗板;⑤加入杂交瘤培养上清,0.1毫升每孔,同时设阳性对照(免疫小鼠血清)、阴性对照(SP2/0培养上清液)和空白对照,室温反应2小时;⑥洗板;⑦加1:6000稀释的辣根过氧化物酶标记的羊抗小鼠IgG,0.1毫升每孔,室温反应1小时;⑧洗板;⑨加入底物室温避光反应5分钟;⑩2摩尔每升硫酸终止反应;450纳米测定其光密度值,以测定值除以阴性≥2.1为阳性。
(5)杂交瘤细胞的克隆化:杂交瘤细胞的克隆化培养按有限稀释法进行,选择抗体检测阳性的杂交瘤孔细胞作适当增殖后,准确计数细胞。用完全DMEM培养基稀释成10个每毫升的细胞悬液接种到已有饲养细胞的96孔培养板中,每孔0.1毫升,10天后观察细胞生长情况,并检测上清液中抗体水平,选择5个抗体滴度最高的,呈单个克隆细胞生长的培养孔,作再次有限稀释。此方法可重复多次,直至单克隆孔抗体检测阳性率为100%。
(6)诱生腹水:在接种杂交瘤细胞前一周,给BALB/C小鼠腹腔注射石蜡油每只0.5毫升,然后每只接种5×106个阳性杂交瘤细胞,10天后收集腹水测定抗体效价。
(7)单克隆抗体的纯化:采用亲和纯化法(Protein G交联的Sepharose)纯化腹水中单克隆抗体。①腹水用冷结合缓冲液稀释3倍后,于4℃10000转每分钟离心15分钟去除沉淀物。②将预装有Sepharose-Protein G的亲和纯化柱用10倍柱床体积的结合缓冲液充分流洗。③将稀释的腹水上柱,控制流速10滴每分钟。④将流穿的腹水重复上柱一次。⑤用20倍柱床体积的结合缓冲液充分洗涤,直至流穿液280纳米吸光值小于0.01。⑥用洗脱缓冲液洗脱结合的单克隆抗体,控制流速10滴每分钟,收集洗脱液于预加有0.1毫升的磷酸钾缓冲液(PH7.9)的收集管中,每管收集0.5毫升含抗体的洗脱液,共收集20管以上。⑦于280纳米检测每管洗脱液的吸光度,并收集吸光值大于0.2的洗脱液。⑧将收集的洗脱液置于透析卡中,并于0.1摩尔每升PH7.4的磷酸盐缓冲液中透析。每隔6小时换液一次,共透析24小时。⑨将透析后的抗体溶液稀释后,于280纳米测蛋白含量。⑩将纯化的抗体分装于小管中,置于低温冰箱备用。
(8)单克隆抗体的亚型鉴定:采用Bio-Rad公司的小鼠单克隆抗体免疫球蛋白分型试剂盒分析。将纯化的单克隆抗体作适当稀释后进行检测,操作严格按试剂盒说明书进行。试验结果为ZJU32-01杂交瘤细胞分泌的单克隆抗体为IgG1、κ型。
结果见附图1。
实施例2.用该单克隆抗体进行H3N2流感病毒的定性检测
本发明制备的抗H3N2流感病毒血凝素蛋白单克隆抗体可以用来定性检测人H3N2流感病毒,鉴定方法可以通过下述方法实现:
H3N2免疫荧光检测法:
(1)将MDCK细胞提前一天以每孔4×104个细胞的密度接种在48孔板中,待细胞长至70%,备用;
(2)取出铺好细胞的细胞板,弃去培养上清,用磷酸盐缓冲液洗一遍,备用;
(3)确定H3N2免疫荧光检测法检测人H3N2流感病毒的特异性:用磷酸盐缓冲液稀释病毒,包括人H1N1病毒(A/Michigan/45/2015)、猪H3N2病毒(A/swine/Zhejiang/19/2019)、禽H3N2病毒(A/duck/Zhejiang/4613/2013)、人H3N2病毒(A/Texas/50/2012)、人H3N2病毒(A/Uruguay/716/2007)、人H3N2病毒(A/Wisconsin/15/09)、人H3N2病毒(A/Victoria/361/2011)、禽H2N7病毒(A/duck/Zhejiang/465/2013)、禽H5N1病毒(A/goose/Zhejiang/727098/2014)、禽H6N1病毒(A/chicken/Zhejiang/1664/2017)、人H7N9病毒(A/Zhejiang/DTID-ZJU01/2013)、禽H9N2病毒(A/chicken/Zhejiang/221/2016)、禽H10N3病毒(A/chicken/Zhejiang/8615/2016)和B/Phuket/3073/2013(乙型流感)稀释后的病毒液感染细胞(感染复数为0.5),在含5%二氧化碳饱和37℃孵箱中培养2小时;
(4)取出细胞板,弃去病毒液,用磷酸盐缓冲液洗细胞2遍,再在每孔中加入200微升的病毒培养液,在含5%二氧化碳饱和37℃孵箱中培养16小时;
(5)取出细胞板,弃去培养上清,用磷酸盐缓冲液洗细胞1遍;
(6)在细胞板中每孔加入4%多聚甲醛固定细胞,室温下固定30分钟,用磷酸盐缓冲液洗3遍;
(7)用0.5%Triton-X100通透细胞,室温下通透30分钟,用磷酸盐缓冲液洗3遍;
(8)用含3%牛血清白蛋白的磷酸盐缓冲液封闭,室温下封闭1小时,弃去牛血清白蛋白溶液;
(9)用磷酸盐缓冲液将单克隆抗体稀释至10微克每毫升,每孔加入200微升,在4℃下孵育过夜,用磷酸盐缓冲液洗3遍;
(10)用含1%牛血清白蛋白溶液稀释荧光二抗至5微克每毫升,每孔加入200微升,在37℃孵箱中避光孵育90分钟,用磷酸盐缓冲液洗3遍;
(11)用脱氧核糖核酸荧光染料(4,6-二脒基-2-苯基吲哚)对细胞核进行染色,室温下避光孵育10分钟,用磷酸盐缓冲液洗3遍;
(12)在荧光显微镜下观察实验结果,观察到绿色荧光即为阳性。检测结果表明,基于本研究开发的抗H3N2流感病毒单克隆抗体ZJU32-01检测H3N2亚型季节性流感病毒具有较好的特异性。
应理解,本发明是结合最佳实施例进行描述的,然而在阅读了本发明的上述内容后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
序列表
<110> 浙江大学医学院附属第一医院
<120> 抗H3N2流感病毒血凝素蛋白单克隆抗体ZJU32-01及其在检测中的应用
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 351
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
caggttcaac tacagcagtc tggagctgag ctgatgaagc ctggggcctc agtgaagata 60
tcctgcaagg ctactggcta catattcagt agctactgga tagaatgggt aaagcagagg 120
cctggacatg gccttgagtg gattggagag attttacctg gaagtggtag gactaactac 180
aaagagattt tcaagggcaa ggccacattc actgcagata catcctccaa cacagcctac 240
atgcaactca gcagcctgac atctgaggac tctgccgtct attactgtgc aagaactcgg 300
actaccggta gtagcgactg gggccaaggc accactctca cagtctcctc a 351
<210> 2
<211> 117
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Ile Phe Ser Ser Tyr
20 25 30
Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Leu Pro Gly Ser Gly Arg Thr Asn Tyr Lys Glu Ile Phe
50 55 60
Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Thr Arg Thr Thr Gly Ser Ser Asp Trp Gly Gln Gly Thr Thr
100 105 110
Leu Thr Val Ser Ser
115
<210> 3
<211> 336
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
gatgttttga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60
atctcttgca gatctagtca gactactgta catagtaatg gaaacaccta tttagaatgg 120
tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180
tttggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240
agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaggttc acatgttccg 300
tacacgttcg gaggggggac caagctggaa ataaaa 336
<210> 4
<211> 112
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Thr Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Phe Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Claims (7)
1.一种抗H3N2流感病毒血凝素蛋白单克隆抗体ZJU32-01,该单克隆抗体亚型为IgG1、κ型,能与H3N2流感病毒血凝素蛋白抗原特异结合。
2.根据权利要求1所述的单克隆抗体ZJU32-01,其特征在于:抗体的重链氨基酸序列如SEQ ID No.2,轻链氨基酸序列如SEQ ID No.4所示。
3.根据权利要求1或2所述的单克隆抗体ZJU32-01,其特征在于:所述抗体由杂交瘤细胞产生。
4.根据权利要求3所述的单克隆抗体ZJU-NP-A3,其特征在于:产生该单克隆抗体的杂交瘤细胞是由免疫的BALB/C小鼠脾淋巴细胞和小鼠骨髓瘤细胞SP2/0经融合、筛选、克隆、传代和反复冻存、复苏后获得的杂交瘤细胞系ZJU32-01,能稳定分泌抗H3N2流感病毒血凝素蛋白的单克隆抗体ZJU32-01。
5.权利要求1或2所述的抗H3N2流感病毒血凝素蛋白的单克隆抗体ZJU32-01在制备H3N2季节性流感病毒检测产品中的应用。
6.根据权利要求5所述的应用,所述检测产品通过免疫荧光技术检测H3N2季节性流感病毒。
7.一种H3N2流感病毒检测产品,其特征在于:包含有权利要求1或2所述的单克隆抗体ZJU32-01。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210039523.1A CN114349852B (zh) | 2022-01-13 | 2022-01-13 | 抗h3n2流感病毒血凝素蛋白单克隆抗体zju32-01及其在检测中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210039523.1A CN114349852B (zh) | 2022-01-13 | 2022-01-13 | 抗h3n2流感病毒血凝素蛋白单克隆抗体zju32-01及其在检测中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114349852A true CN114349852A (zh) | 2022-04-15 |
CN114349852B CN114349852B (zh) | 2024-03-12 |
Family
ID=81109184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210039523.1A Active CN114349852B (zh) | 2022-01-13 | 2022-01-13 | 抗h3n2流感病毒血凝素蛋白单克隆抗体zju32-01及其在检测中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114349852B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114957456A (zh) * | 2022-05-28 | 2022-08-30 | 浙江大学医学院附属第一医院 | 甲型流感病毒血凝素蛋白的单克隆抗体zju-a1a3及其在检测中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101561664B1 (ko) * | 2014-12-02 | 2015-10-20 | 대한민국 | A/h3n2 인플루엔자 바이러스의 ha 단백질에 특이적인 항체, 및 이를 생산하는 하이브리도마 세포주 |
CN106381288A (zh) * | 2016-08-31 | 2017-02-08 | 广州优迪生物科技有限公司 | 一种抗h3n2亚型犬流感病毒核蛋白单克隆抗体杂交瘤2d10及单克隆抗体 |
CN112830966A (zh) * | 2021-03-03 | 2021-05-25 | 浙江大学医学院附属第一医院 | 抗h6n1禽流感病毒血凝素蛋白单克隆抗体zju61-01及其应用 |
-
2022
- 2022-01-13 CN CN202210039523.1A patent/CN114349852B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101561664B1 (ko) * | 2014-12-02 | 2015-10-20 | 대한민국 | A/h3n2 인플루엔자 바이러스의 ha 단백질에 특이적인 항체, 및 이를 생산하는 하이브리도마 세포주 |
CN106381288A (zh) * | 2016-08-31 | 2017-02-08 | 广州优迪生物科技有限公司 | 一种抗h3n2亚型犬流感病毒核蛋白单克隆抗体杂交瘤2d10及单克隆抗体 |
CN112830966A (zh) * | 2021-03-03 | 2021-05-25 | 浙江大学医学院附属第一医院 | 抗h6n1禽流感病毒血凝素蛋白单克隆抗体zju61-01及其应用 |
Non-Patent Citations (2)
Title |
---|
NCBI: ""immunoglobulin light chain variable region, partial [Mus musculus], AAF88053.1"", 《GENBANK》, pages 1 - 2 * |
陈艳 等: ""H3N2 亚型猪流感病毒血凝素单克隆抗体的制备及其抗原表位的鉴定"", 《中国预防兽医学报》, vol. 43, no. 6, pages 633 - 638 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114957456A (zh) * | 2022-05-28 | 2022-08-30 | 浙江大学医学院附属第一医院 | 甲型流感病毒血凝素蛋白的单克隆抗体zju-a1a3及其在检测中的应用 |
CN114957456B (zh) * | 2022-05-28 | 2024-03-12 | 浙江大学医学院附属第一医院 | 甲型流感病毒血凝素蛋白的单克隆抗体zju-a1a3及其在检测中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114349852B (zh) | 2024-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112225797B (zh) | 一种抗SARS-CoV-2核衣壳蛋白的单克隆抗体及应用 | |
CN111153991A (zh) | 一种人SARS-CoV-2单克隆抗体及其制备方法和应用 | |
JP3584990B2 (ja) | 抗ヒトインフルエンザウイルス抗体 | |
EP1970707A1 (en) | Method for detection of virulent strain of influenza type-a virus | |
CN110144007B (zh) | 抗h7n9禽流感病毒血凝素蛋白单克隆抗体zju79-01及其应用 | |
CN105087497A (zh) | 杂交瘤细胞株zjeb8-01、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 | |
CN102010472A (zh) | 一种抗d-二聚体单克隆抗体及其用途 | |
CN105112375A (zh) | 杂交瘤细胞株zjed0-02、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 | |
CN114349852B (zh) | 抗h3n2流感病毒血凝素蛋白单克隆抗体zju32-01及其在检测中的应用 | |
CN112175072B (zh) | 抗h5亚型禽流感病毒血凝素蛋白单克隆抗体zju5-01及其应用 | |
CN114349853A (zh) | 抗h1n1流感病毒血凝素蛋白中和性单克隆抗体zju11-01及其应用 | |
CN114539397A (zh) | 具有中和活性的抗h1n1流感病毒血凝素蛋白单克隆抗体zcmu-h1n1及其应用 | |
CN113024666B (zh) | 具有广谱性识别a型流感病毒np蛋白的单克隆抗体及其应用 | |
CN112830966B (zh) | 抗h6n1禽流感病毒血凝素蛋白单克隆抗体zju61-01及其应用 | |
CN113402604A (zh) | 快速检测病毒的试剂盒及其制备方法 | |
CN112851803B (zh) | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体zju10-01及其应用 | |
CN114426576A (zh) | 抗h3n2流感病毒核蛋白单克隆抗体zju-np-a3及其在检测中的应用 | |
CN108872580B (zh) | 一种检测新型鹅细小病毒的胶体金试纸条及其制备方法 | |
CN114456262A (zh) | 抗h1n1流感病毒核蛋白单克隆抗体zju-np-a1及其在检测中的应用 | |
CN116143909B (zh) | 一种抗hiv-1 p24的抗体及其制备方法和用途 | |
CN116462754A (zh) | 一种识别犬瘟热病毒n蛋白的单克隆抗体、检测试剂及应用 | |
CN114957456B (zh) | 甲型流感病毒血凝素蛋白的单克隆抗体zju-a1a3及其在检测中的应用 | |
CN112724249B (zh) | 抗h9亚型禽流感病毒血凝素蛋白单克隆抗体zju9-01及其应用 | |
CN115850460A (zh) | 抗y系乙型流感病毒血凝素蛋白单克隆抗体2h6及其在检测中的应用 | |
CN116063467A (zh) | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |